Page 4 - Diabetes

Researchers reveal Covid-19 infection increases diabetes, disease risk

This research, Kwan says, is one piece of the puzzle that will help researchers understand how to prevent metabolic as well as cardiovascular disease risk in the future

Drug firm Glenmark gets USFDA nod for generic diabetes drug to market in US

Drug firm Glenmark said it has received approval from the US health regulator to market a generic medication to treat diabetes in the American market. Glenmark Pharmaceuticals Inc, USA, a unit of the company, has received tentative approval from the US Food & Drug Administration (US FDA) for Saxagliptin Tablets in strengths of 2.5 mg and 5 mg, the Mumbai-based drug maker said in a statement. The company's product is the generic version of AstraZeneca AB's Onglyza tablets (2.5 mg and 5 mg), it added. According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza tablets (2.5 mg and 5 mg) achieved annual sales of around USD 122.3 million. Glenmark said its current portfolio consists of 179 products authorised for distribution in the US marketplace. The drug firm has 46 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added. In addition to these internal filings, Glenmark continues to identify and explore external development ...

Covid's omicron variant, thought to be milder, can increase diabetes risk

Omicron has been seen as a milder version of Covid compared with earlier strains, leading to lower rates of hospitalization and death than delta and the strain that first emerged from China

Best Natural Treatment For Diabetes: Home Remedies For Type 2 Diabetes

.

Cut down on sugar

Multiple levers are available to improve public health

Glenmark Pharma launches combination drug for Type 2 diabetic patients

Glenmark Pharmaceuticals Ltd on Wednesday said it has launched triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India for diabetic patients. This fixed-dose combination offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses, the company said in a statement. It has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg), Pioglitazone (15 mg) and Metformin (500mg/1000mg) in a sustained release (SR) formulation, it added. "Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38 per cent compared to the global incidence of 15 per cent," Glenmark Pharmaceuticals EVP & Business Head - India Formulations Alok Malik said. The market .

Torrent Pharma, Boehringer Ingelheim India to co-market diabetes drug

Torrent Pharmaceuticals on Wednesday said it has inked a pact with Boehringer Ingelheim India to co-market diabetes drug and its combinations in the country. The company has inked an agreement to jointly sell Cospiaq (Empagliflozin), Cospiaq Met (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin). Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. It is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. "I am confident that the launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall diabetes and cardiovascular portfolios and bolster our position as a leading player in these high growth segments within the Indian pharmaceutical market," Torrent Pharmaceuticals Director Aman Mehta said in a statement. Boehringer Ingelheim India Managing Direct

Artificial intelligence can be helpful in diabetes monitoring, prevention

Artificial intelligence can be used to turn a continuous glucose monitor (CGM) into a potent tool for diabetes monitoring and prevention, suggests researchers at Klick Applied Sciences

AstraZeneca India gets regulator's approval to market anti-diabetes drug

Drug firm AstraZeneca India on Tuesday said it has received approval from the country's drug regulator to market anti-diabetes medication Dapagliflozin. The company said it has received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD). Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalisations due to heart failure in adults with progressive chronic kidney disease, the drug firm said. The approval is applicable for both diabetic and non-diabetic CKD patients, it added. CKD is one of the leading causes of hospitalisation globally and in India, representing a significant clinical and economic burden. "The timely approval of Dapagliflozin from the CDCSCO committee with the additional indication is a huge boost for nephrologists across the country .

Type 2 diabetes linked with gestational diabetes in S Asian women: Study

Women of South Asian origin may be more likely to experience gestational diabetes due to the same complex genetics that increases their chance of acquiring type 2 diabetes, according to a study

Covid can deteriorate diabetes, associated heath disease: Scientist

Covid can alter a person's genetic makeup which can enhance the proliferation of disease and cause further deterioration in diabetes and associated heart disease, an Indian-origin researcher revealed

IRCTC allowed to customise menu for diabetics, infants, health aficionados

The Railway Board has given its catering and tourism arm IRCTC the flexibility to customise its menu to include local and regional cuisines as well as food suitable for diabetics, infants and health aficionados. According to a note sent by the Railway Board to the Indian Railway Catering and Tourism Corporation (IRCTC), the move is aimed at improving catering services on trains and give passengers more options. "As a measure to improve catering services on trains, it has been decided to give IRCTC the flexibility to customize the menu so as to include items of regional cuisines/preferences, seasonal delicacies, requirement during festivals, food items as per the preferences of different group of passengers such as diabetic food, baby food, health food options, including millet-based local products among others," the note said. At present, the IRCTC has to get the menus, comprising mostly of standardised food items and beverages, approved by the Railway Board before it can introduce

World Health Organization calls for increased access to diabetes education

The WHO on Monday called for increased access to quality diabetes education for healthcare workers, the public and people living with diabetes as part of efforts to ensure better access to quality and affordable care for the disease. Globally, around 422 million people have diabetes, and 1.5 million deaths are directly attributed to diabetes every year, Dr Poonam Khetrapal Singh, WHO Regional Director for South-East Asia, said on the World Diabetes Day. In the WHO South-East Asia Region, more than 96 million people are estimated to have diabetes, and another 96 million to be pre-diabetic, causing at least 600,000 deaths annually, she said. "By 2045, unless urgent action is taken, the prevalence of diabetes in the region is expected to increase by 68 per cent," Singh said in a statement. Diabetes is a chronic metabolic disease. If detected late or improperly managed, it can lead to serious and life-threatening damage to the heart, blood vessels, eyes, kidneys and nerves. The risk o

Are sugar alternatives actually healthy? Here's what experts suggest

On World Diabetes Day, Business Standard spoke with experts to demystify sugar substitutes that have found a way into our diet

Study finds how AI helps to predict diabetes complications in patients

In the United States, more than 37 million individuals have diabetes, yet many of them don't receive immediate treatment, which can result in expensive or even fatal consequences

More uncovered on link between late-night eating and weight gain, diabetes

Scientists have uncovered details of the metabolism of late-night eating associated with weight gain and diabetes, according to a study. While the connection between time, sleep and obesity is well-known, it is misunderstood because research showed that overnutrition can disrupt circadian rhythms and change fat tissue, the study by a team of researchers from the Northwestern University stated. It also showed that energy release may be the molecular mechanism through which the internal clocks of human beings control energy balance. From this understanding, the scientists also found that daytime is the ideal time in the light environment of the Earth's rotation when it is most optimal to dissipate energy as heat. These findings, published in the journal Science, have broad implications from dieting to sleep loss and the way patients who require long-term nutritional assistance are fed. "It is well known, albeit poorly understood, that insults to the body clock are going to be insult

Physical inactivity may cost the world $300 bn between 2020 and 2030: WHO

Around 500 mn people will develop heart disease, obesity, diabetes or other non-communicable diseases (NCDs) due to physical inactivity, WHO's 'Global Status Report on Physical Activity 2022' says

Researchers develop new 3d technique to revolutionise diabetes treatment

A new bandage treatment, known as a scaffold, to treat diabetic foot ulcers, which is cost-effective while improving patient outcomes, has been designed by researchers at Queen's University Belfast

Covid-19 linked with higher risk of type 1 diabetes in young people: Study

Children and adolescents infected with COVID-19 show a substantially higher risk of developing type 1 diabetes (T1D), according to a study of over 1 million patients aged 18 and younger. The findings, published recently in the journal JAMA Network Open, showed a 72 per cent increase in new diagnoses of T1D in younger COVID-19 patients in the six months following their diagnosis. However, the research emphasised that it is unclear whether COVID-19 triggers new onset of T1D. "Type 1 diabetes is considered an autoimmune disease," said Pamela Davis, a professor at the Case Western Reserve School of Medicine, US, and corresponding author of the study. "It occurs mostly because the body's immune defenses attack the cells that produce insulin, thereby stopping insulin production and causing the disease. COVID has been suggested to increase autoimmune responses, and our present finding reinforces that suggestion," Davis said. The team analysed the de-identified electronic health records o

Diabetes burden: India lost 45 years of healthy life per person in 2021

By 2040, Type 1 diabetes cases to increase by 116% in India, says Lancet study